Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction
ConditionDiaphragm Injury
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorStanford University
About this trial
We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.
Eligibility criteria
Qualifiers
Patients undergoing esophagectomy
Disqualifiers
Patients with more than mild pulmonary dysfunction
Patients with any neuromuscular disease that might compromise diaphragm function
Patients with abnormal liver or kidney function
Patients taking any immunosuppressant medication (including prednisone) or antifungal medications
Trial design
Treatments tested in this trial
- Tofacitinib 10 MG [Xeljanz]
- Placebo to match Tofacitinib
Treatment groups
70 Participants
are divided into 2 treatment groupsSponsors and collaborators
Stanford University
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Source ClinicalTrials.gov